Express interest
TherapyScienceTeamInvestorsContact Express interest

A night-time brain therapy for Alzheimer's disease and memory disorders.

Vguard is a non-invasive stimulator worn during sleep. Gentle impulses reach the vagus nerve through electrodes at the outer ear, while the brain consolidates memory.

Express interest Physicians and neurophysiologists
One night with Vguard 02:12 REM sleep Stimulation window REM sleep. A stage in which memory consolidation processes are most active.
Schematic illustration. Not patient data, stimulation parameters not shown.Sleep stages: Awake, REM, N1 to N3
Class IIa medical device CE marked under MDR 2017/745 Notified body TÜV Rheinland (NB 0197) 10+ peer-reviewed publications

Memory is organised while we sleep. Vguard works in those hours.

The therapy is administered at night, when physiological memory consolidation takes place. No surgery and no implanted electrodes, only a headband and small electrodes at the ear.

Therapy during sleep

Used every night, taking advantage of the period when the brain consolidates and organises information.

Built on the neurophysiology of memory

Developed from years of research into hippocampal theta rhythm, a mechanism associated with learning and memory.

Aligned with natural sleep cycles

Stimulation protocols are tuned to REM sleep and other stages in which memory consolidation is most active.

Introducing Vguard

A therapeutic system of a neurostimulation device, specially designed ear electrodes and software that supports correct use. Designed for regular, long-term use as recommended by the physician.

The Vguard set: headband with stimulator on a mannequin head, packaging, electrode sets and cable
StimulatorDelivers controlled electrical impulses to the auricular branch of the vagus nerve.
HeadbandHolds the device and electrodes in position through the night.
Electrode setsDisposable, replaced daily. A patented electrode-skin interface allows higher intensities without discomfort.
The setDevice, a year of disposable electrodes and technical support.

Non-invasive

Electrodes sit on a specific area of the outer ear. Nothing is implanted.

Comfortable at night

Each session is optimised for safety, comfort and therapeutic value.

Physician-led

A doctor decides whether therapy can begin and follows its use.

Ten years in development

Over a decade of research and development behind the technology.

From the ear to the brain's memory networks.

Electrodes at the outer ear reach the auricular branch of the vagus nerve, so the therapy needs no surgery and no implant.

Outer ear

Gentle impulses are delivered through electrodes positioned on the auricular branch of the vagus nerve.

Brainstem

The signal travels through structures in the brainstem along vagus nerve pathways.

Memory networks

It modulates neural networks involved in attention, learning and memory, including hippocampal activity.

Vagus nerve stimulation has been used clinically in neurology and psychiatry for more than 25 years, including in epilepsy and treatment-resistant depression.

Every night, the same five steps.

  1. 1Prepare the device and fresh electrodes.
  2. 2Position the electrodes and put on the headband.
  3. 3Start the night-time session.
  4. 4Sleep. Stimulation runs non-invasively.
  5. 5Repeat regularly, as the physician recommends.

Intended for people with Alzheimer's disease or mild cognitive impairment.

For patients

Independence and a sense of security. A therapy that supports memory and cognitive function, to help preserve what matters most.

For families and caregivers

Technology designed to reduce the time and financial burden of care, so families can focus on staying close.

For healthcare systems

Solutions that can help reduce the burden on caregivers, limit costs and meet growing demand.

How therapy starts, step by step

Ten years of research, published in peer-reviewed journals.

Preclinical and neurophysiological studies showed the effect of vagus nerve stimulation on type II theta rhythm in the hippocampus. Development continued with a randomised, double-blind, placebo-controlled medical experiment.

PLOS ONE, 2018

Medial septal cholinergic mediation of hippocampal theta rhythm induced by vagal nerve stimulation

Broncel A., Bocian R., Kłos-Wojtczak P., Konopacki J.

Brain Research Bulletin, 2018

Some technical issues of vagal nerve stimulation. An approach using a hippocampal formation theta rhythm

Broncel A., Bocian R., Kłos-Wojtczak P., Konopacki J.

2019

Vagal nerve stimulation as a promising tool in the improvement of cognitive disorders

Broncel A., Bocian R., Kłos-Wojtczak P., Kulbat-Warycha K., Konopacki J.

All publications and the development programme

Dr Adam Broncel, Chief Medical Officer

“The opportunity to turn scientific innovation into real solutions for devastating conditions like Alzheimer's. Knowing that our work can change patients' lives gives me purpose every single day.”

Adam Broncel, MD, PhD · Chief Medical Officer, led the first human trials of the Vguard method

Common questions

Who can start Vguard therapy?

Vguard is intended for Alzheimer's disease and mild cognitive impairment, in line with its intended purpose. A physician decides whether a patient qualifies.

Does it require surgery?

No. Electrodes are placed on a specific area of the outer ear. No stimulating component is implanted.

Why is it used during sleep?

Sleep is when memory consolidation and organisation take place, and the protocols are tuned to the sleep stages where this is most active.

What does a year of therapy cost?

PLN 22,000 for one year, including the device, daily disposable electrode sets for 12 months and technical support.

Is Vguard certified?

Vguard is a Class IIa medical device, CE marked under Regulation (EU) 2017/745, with conformity assessment by TÜV Rheinland LGA Products GmbH (NB 0197).

Talk to the Cogniguard team.

Patients and families

Leave your details and we will explain the organisational steps toward medical qualification.

Express interest

Physicians and researchers

Clinical and scientific questions, and collaboration on upcoming studies.

Write to our medical team

Investors and partners

Join us in advancing Alzheimer's care, in Europe and beyond.

Contact the CEO office